Nathalie LeVasseur

Dr. Nathalie LeVasseur

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2018 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
ARAndrew Robinson
Andrew Robinson
OSOsama Souied
Osama Souied
ABA. Brianne Bota
A. Brianne Bota
NLNathalie LeVasseur
Nathalie LeVasseur
CSCarol Stober
Carol Stober
MCMark Clemons
Mark Clemons

18 November 2019 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
NLNathalie LeVasseur
Nathalie LeVasseur
JSJ. Sun
J. Sun
LGL. Gondara
L. Gondara
RDR. Diocee
R. Diocee
CSC. Speers
C. Speers
SCS. Chia
S. Chia

1 November 2016 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
NLNathalie LeVasseur
Nathalie LeVasseur
MCMark Clemons
Mark Clemons
BHBrian Hutton
Brian Hutton
RSRisa Shorr
Risa Shorr
CJCarmel Jacobs
Carmel Jacobs

1 August 2018 in Current Oncology
Verified
Journal Article
Open access
NLNathalie LeVasseur
Nathalie LeVasseur
CSC. Stober
C. Stober
KDK. Daigle
K. Daigle
ARA. Robinson
A. Robinson
SMS. McDiarmid
S. McDiarmid
MCMark Clemons
Mark Clemons
Background: Despite advances in systemic therapy choices for patients with early-stage breast cancer, optimal practices for intravenous (IV) access remain unknown. That lack of knowledge holds particularly true for the use of central venous access devices (cvads) such as peripherally inserted central catheters (piccs) and implanted vascular access devices (ports). Methods: Using a survey of Canadian oncologists and oncology nurses responsible for the care of breast cancer patients, we evaluated current access practices, perceptions of complications, and perceptions of risk, and we estimated complication rates and evaluated perceived risk factors for lymphedema. Results: Survey responses were received from 25 physicians and 57 oncology nurses. Administration of trastuzumab or an anthracycline was associated with a higher likelihood of a cvad being recommended. Other factors associated with recommendation of a cvad included prior difficult IV access and a recommendation from the chemotherapy nurse. Although the complication rates perceived to be associated with the use of piccs and ports remained high, respondents felt that cvads might improve patient quality of life. Risk factors perceived to be associated with the risk of lymphedema were axillary lymph node dissection, radiation to the axilla, and line-associated infection. Factors known to be unrelated to lymphedema risk (specifically, blood draws and blood pressure measurement) continue to be perceived as posing a higher risk. Conclusions: Despite widespread use of chemotherapy for patients with breast cancer, the type of venous access used for treatment varies significantly, as do perceptions about the risks of cvad use and the risk for lymphedema development. Further prospective studies are needed to identify best-practice strategies.

1 August 2018 in Current Oncology
Verified
Journal Article
Open access
NLNathalie LeVasseur
Nathalie LeVasseur
CSC. Stober
C. Stober
MIM. Ibrahim
M. Ibrahim
SGS. Gertler
S. Gertler
JHJ. Hilton
J. Hilton
MCMark Clemons
Mark Clemons
Background: The choice of vascular access for systemic therapy administration in breast cancer remains an area of clinical equipoise, and patient preference is not consistently acknowledged. Using a patient survey, we evaluated the patient experience with vascular access during treatment for early-stage breast cancer and explored perceived risk factors for lymphedema. Methods: Patients who had received systemic therapy for early-stage breast cancer were surveyed at 2 Canadian cancer centres. Results: Responses were received from 187 patients (94%). The route of vascular access was peripheral intravenous line (IV) in 24%, a peripherally inserted central catheter (picc) in 42%, and a surgically inserted central catheter (port) in 34%. Anthracycline-based regimens were associated with a greater use of central vascular access devices (cvads— that is, a picc or port; 86/97, 89%). Trastuzumab use was associated with greater use of ports (49/64, 77%). Although few patients (7%) reported being involved in the decisions about vascular access, most were satisfied or very satisfied (88%) with their access type. Patient preference centred mainly on avoiding delays in the initiation of chemotherapy. Self-reported rates of complications (183 evaluable responses) were infiltration with peripheral IVs (9/44, 20%), local skin infections with piccs (7/77, 9%), and thrombosis with ports (4/62, 6%). Perceived risk factors for lymphedema included use of the surgical arm for blood draws (117/156, 75%) and blood pressure measurement (115/156, 74%). Conclusions: Most patients reported being satisfied with the vascular access used for their treatment. Improved education and understanding about the evidence-based requirements for vascular access are needed. Perceived risk factors for lymphedema remain variable and are not evidence-based.

7 July 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
MPMehrnoosh Pauls
Mehrnoosh Pauls
Stephen ChiaStephen Chia
Stephen Chia
NLNathalie LeVasseur
Nathalie LeVasseur
Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC.